Optimizing the use of anti VEGF targeted therapies in patients with ...

This article presents an overview of the actual evidence for the use of agents that target angiogenesis in the treatment of mCRC.

Optimizing the use of anti VEGF targeted therapies in patients with metastatic colorectal cancer: review of literature ... Clujul Med. 2018;91(1):12-17. doi: ...

Optimizing Anti-VEGF Treatment Outcomes for Patients with ...

Although less common, laser surgery may also be used to destroy abnormal blood vessels in nAMD. The management of nAMD has been transformed by ...

Optimizing Anti-VEGF Treatment Outcomes for Patients with ...

SUMMARY: Three anti-VEGF therapies currently form the mainstay of treatment for nAMD, including 2 therapies approved by the FDA for treatment of ...

Optimizing the Anti-VEGF Treatment Strategy for Neovascular Age ...

After the initial pivotal trials of anti-VEGF therapy, the variable dosing regimens pro re nata (PRN), Treat-and-Extend, and Observe-and-Plan, a recently ...

Optimizing treatment of renal cell carcinoma with VEGFR-TKIs

Highlights · Anti-angiogenic treatment is an important option that has changed the therapeutic landscape in cancer patients, particularly those with renal cell ...

Reassessing vascular endothelial growth factor (VEGF) in anti ...

Considering VEGF is a primary promoter of tumor angiogenesis, many anti-angiogenic treatments already in use in the treatment of human cancer are focused on ...

Angiogenic signaling pathways and anti-angiogenic therapy for cancer

The most widely used anti-angiogenic agents include monoclonal antibodies and tyrosine kinase inhibitors (TKIs) targeting vascular endothelial ...

Optimizing sequential treatment with anti-EGFR and VEGF mAb in ...

Recently, a few small clinical studies revealed that prior use of bevacizumab may impair the effect of cetuximab or panitumumab. Preclinical ...

The Role of VEGF and EGFR Inhibition: Implications for Combining ...

Conversely, (over)activation of VEGF expression independent of EGFR signaling is thought to be one way that tumors become resistant to anti-EGFR therapy (4).

Defining response to anti-VEGF therapies in neovascular AMD | Eye

The overall effectiveness of anti-VEGF therapies in n-AMD is unquestionable. However, not all patients benefit in an identical manner and, as ...

Cancer combination therapies by angiogenesis inhibitors

As the first VEGF-targeted agent approved by FDA, bevacizumab, is used since February 2004, for the treatment of patients suffering from ...

Understanding and targeting resistance to anti-angiogenic therapies

FDA approved agents with anti-VEGF properties include bevacizumab, ziv-aflibercept, and multiple small molecule RTK inhibitors (i.e., sorafenib, sunitinib, ...

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of ...

When the VEGF-A-targeting monoclonal antibody bevacizumab (Avastin®) entered clinical practice more than 15 years ago, it was one of the first targeted ...

[PDF] Optimizing Anti-VEGF Treatment Outcomes for Patients with ...

New clinical evidence and insights into expert clinical practice discussed in this article can support managed care professionals in the key role they play ...

Optimizing Anti-VEGF Treatment Outcomes for Patients with ...

Early initiation of antivascular endothelial growth factor (VEGF) therapy can slow disease progression and preserve vision in patients with neovascular AMD ( ...

Optimizing Anti-VEGF Treatment Outcomes for Patients with ...

SUMMARY: Three anti-VEGF therapies currently form the mainstay of treatment for nAMD, including 2 therapies approved by the FDA for treatment of nAMD ( ...

Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti ...

Optimal scheduling of anti-angiogenic drugs is important for improving efficacy of combination therapy in patients with advanced-stage cancer.

Mechanistic insights into the heterogeneous response to anti‐VEGF ...

We applied the model to investigate the effects of VEGF-targeted treatment on tumor cells and endothelial cells. We identified that tumors with ...

Capecitabine reverses tumor escape from anti-VEGF through the ...

Anti-VEGF treatment increased the number of intratumoral CD11bhigh/Gr-1high cells ... Shojaei et al. used B16F1 melanomas and LLC murine lung ...